BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 27.2] [Reference Citation Analysis]
Number Citing Articles
1 Mazza G, Al-Akkad W, Rombouts K. Engineering in vitro models of hepatofibrogenesis. Adv Drug Deliv Rev. 2017;121:147-157. [PMID: 28578016 DOI: 10.1016/j.addr.2017.05.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
2 Clark P. Serum markers for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;8:29-33. [PMID: 31041059 DOI: 10.1002/cld.565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Shen J, He L, Li C, Wen T, Chen W, Lu C, Yan L, Li B, Yang J. Prognostic nomograms for patients with resectable hepatocelluar carcinoma incorporating systemic inflammation and tumor characteristics. Oncotarget 2016;7:80783-93. [PMID: 27811374 DOI: 10.18632/oncotarget.13038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
5 Delgado TC, Barbier-Torres L, Zubiete-Franco I, Lopitz-Otsoa F, Varela-Rey M, Fernández-Ramos D, Martínez-Chantar ML. Neddylation, a novel paradigm in liver cancer. Transl Gastroenterol Hepatol 2018;3:37. [PMID: 30050997 DOI: 10.21037/tgh.2018.06.05] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
6 Barone M, Di Leo A, Sabbà C, Mazzocca A. The perplexity of targeting genetic alterations in hepatocellular carcinoma. Med Oncol 2020;37:67. [PMID: 32699957 DOI: 10.1007/s12032-020-01392-8] [Reference Citation Analysis]
7 Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, Chen J, Hu YW, Zheng L, Wang Q. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer 2018;17:93. [PMID: 29803224 DOI: 10.1186/s12943-018-0841-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
8 Akkın S, Varan G, Bilensoy E. A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers. Molecules 2021;26:3382. [PMID: 34205019 DOI: 10.3390/molecules26113382] [Reference Citation Analysis]
9 白春阳, 王红雷. 芍药苷通过调节Caspase3活性及核因子κB信号通路诱导HepG2肝癌细胞凋亡. 世界华人消化杂志 2015; 23(22): 3582-3586 [DOI: 10.11569/wcjd.v23.i22.3582] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Chen X, Wang L, Wang H. LINC01638 lncRNA promotes cancer cell proliferation in hepatocellular carcinoma by increasing cancer cell glucose uptake. Oncol Lett 2019;18:3811-6. [PMID: 31516592 DOI: 10.3892/ol.2019.10682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mauri G, Cova L, Ierace T, Baroli A, Di Mauro E, Pacella CM, Goldberg SN, Solbiati L. Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. Cardiovasc Intervent Radiol. 2016;39:1023-1030. [PMID: 26911732 DOI: 10.1007/s00270-016-1313-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
12 Tan CK. Peretinoin as an adjuvant therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:1201-10. [PMID: 27649418 DOI: 10.1080/17474124.2016.1238303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yeon JE, Byun KS, Kim HS, Kim JH, Kim SU. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer 2019;19:363. [PMID: 30991968 DOI: 10.1186/s12885-019-5495-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Sun Y, Lei B, Huang Q. SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR). Med Sci Monit 2019;25:6244-54. [PMID: 31427562 DOI: 10.12659/MSM.915729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Singh H, Kim SJ, Kang DH, Kim H, Sharma A, Kim WY, Kang C, Kim JS. Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity. Chem Commun 2018;54:12353-6. [DOI: 10.1039/c8cc05175e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Rădulescu M, Holban AM, Mogoantă L, Bălşeanu TA, Mogoșanu GD, Savu D, Popescu RC, Fufă O, Grumezescu AM, Bezirtzoglou E, Lazar V, Chifiriuc MC. Fabrication, Characterization, and Evaluation of Bionanocomposites Based on Natural Polymers and Antibiotics for Wound Healing Applications. Molecules 2016;21:E761. [PMID: 27294905 DOI: 10.3390/molecules21060761] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
17 Puijk RS, Ruarus AH, Scheffer HJ, Vroomen LGPH, van Tilborg AAJM, de Vries JJJ, Berger FH, van den Tol PMP, Meijerink MR. Percutaneous Liver Tumour Ablation: Image Guidance, Endpoint Assessment, and Quality Control. Can Assoc Radiol J 2018;69:51-62. [PMID: 29458955 DOI: 10.1016/j.carj.2017.11.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
18 Wang Z, Zhang H, Zhou J, Zhang X, Chen L, Chen K, Huang Z. Eriocitrin from lemon suppresses the proliferation of human hepatocellular carcinoma cells through inducing apoptosis and arresting cell cycle. Cancer Chemother Pharmacol 2016;78:1143-50. [PMID: 27766389 DOI: 10.1007/s00280-016-3171-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
19 Zhang X, Lin C, Chan W, Liu K, Lu A, Lin G, Hu R, Shi H, Zhang H, Yang Z. Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice. Molecules 2019;24:E3332. [PMID: 31547459 DOI: 10.3390/molecules24183332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Li W, Wang Y, Gao W, Zheng J. Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy: A retrospective study. Medicine (Baltimore) 2016;95:e5422. [PMID: 27893681 DOI: 10.1097/MD.0000000000005422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
21 Gong Q, Gao X, Liu W, Hong T, Chen C. Drug-Loaded Microbubbles Combined with Ultrasound for Thrombolysis and Malignant Tumor Therapy. Biomed Res Int 2019;2019:6792465. [PMID: 31662987 DOI: 10.1155/2019/6792465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Nie H, Wang Y, Yang X, Liao Z, He X, Zhou J, Ou C. Clinical Significance and Integrative Analysis of the SMC Family in Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:727965. [PMID: 34527684 DOI: 10.3389/fmed.2021.727965] [Reference Citation Analysis]
23 Yin T, Li W, Zhao P, Wang Y, Zheng J. Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma. Clin Radiol 2017;72:136-40. [PMID: 27890422 DOI: 10.1016/j.crad.2016.10.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
24 Shen J, He L, Li C, Wen T, Chen W, Lu C, Yan L, Li B, Yang J. Nomograms to Predict the Individual Survival of Patients with Solitary Hepatocellular Carcinoma after Hepatectomy. Gut Liver 2017;11:684-92. [PMID: 28651303 DOI: 10.5009/gnl16465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
25 Wang W, Smits R, Hao H, He C. Wnt/β-Catenin Signaling in Liver Cancers. Cancers (Basel) 2019;11:E926. [PMID: 31269694 DOI: 10.3390/cancers11070926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 16.0] [Reference Citation Analysis]
26 Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Liu Z, Zhong Y, Chen YJ, Chen H. SOX11 regulates apoptosis and cell cycle in hepatocellular carcinoma via Wnt/β-catenin signaling pathway. Biotechnol Appl Biochem 2019;66:240-6. [PMID: 30517979 DOI: 10.1002/bab.1718] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
28 Huang W, Chen Q, Dai J, Zhang Y, Yi Y, Wei X, Wu Z. miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC). J Gastrointest Oncol 2021;12:1811-22. [PMID: 34532130 DOI: 10.21037/jgo-21-319] [Reference Citation Analysis]
29 Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019;13:821-5. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653-667. [PMID: 26493646 DOI: 10.1038/nrc4017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 158] [Article Influence: 33.2] [Reference Citation Analysis]
31 Moris D, Beal EW, Chakedis J, Burkhart RA, Schmidt C, Dillhoff M, Zhang X, Theocharis S, Pawlik TM. Role of exosomes in treatment of hepatocellular carcinoma. Surgical Oncology 2017;26:219-28. [DOI: 10.1016/j.suronc.2017.04.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
32 Dekervel J, Popovic D, van Malenstein H, Windmolders P, Heylen L, Libbrecht L, Bulle A, De Moor B, Van Cutsem E, Nevens F, Verslype C, van Pelt J. A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol 2016;9:139-46. [PMID: 27084430 DOI: 10.1016/j.tranon.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Cai Y, Xu Y, Chan HF, Fang X, He C, Chen M. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy. Mol Pharm 2016;13:699-709. [PMID: 26808002 DOI: 10.1021/acs.molpharmaceut.5b00677] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
34 Hu T, Zhang K, Pan D, Pan X, Yang H, Xiao J, Shen X, Luo P. Inhibition Effect of Dictyophora Polysaccharides on Human Hepatocellular Carcinoma Cell Line HCC-LM3. Med Sci Monit 2020;26:e918870. [PMID: 32374722 DOI: 10.12659/MSM.918870] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Liu X, Huang H, Gao Y, Zhou L, Yang J, Li X, Li Y, Zhao H, Su S, Ke C, Pei Z. Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector. J Cancer 2020;11:2192-200. [PMID: 32127946 DOI: 10.7150/jca.39579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
36 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Schöler D, Castoldi M, Jördens MS, Schulze-Hagen M, Kuhl C, Keitel V, Luedde T, Roderburg C, Loosen SH. Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series. PLoS One 2021;16:e0255983. [PMID: 34407090 DOI: 10.1371/journal.pone.0255983] [Reference Citation Analysis]
38 Forner A, Reig M. Does ramucirumab deserve a second chance for liver cancer? Lancet Oncol 2015;16:751-2. [PMID: 26095780 DOI: 10.1016/S1470-2045(15)00053-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chatterjee S, Patra D, Chakraborti U, Sengupta D, Ghosh P, Basu A, Sadhukhan GC, Chowdhury KD. Association of p38MAPK‐p53‐Fas aggregation in S‐allyl cysteine mediated regulation of hepatocarcinoma. Environmental Toxicology 2019;34:928-40. [DOI: 10.1002/tox.22764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Daisy PS, Shreyas KS, Anitha TS. Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications. Mol Biotechnol 2021;63:93-108. [PMID: 33386579 DOI: 10.1007/s12033-020-00289-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 29.3] [Reference Citation Analysis]
42 Liao S, Chen H, Liu M, Gan L, Li C, Zhang W, Lv L, Mei Z. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway. Aging (Albany NY) 2020;12:1527-44. [PMID: 31969493 DOI: 10.18632/aging.102698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
43 Guo X, Wang Y. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med 2020;9:5235-46. [PMID: 32462698 DOI: 10.1002/cam4.3046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
44 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
45 Li B, Lv L, Li W. 1,25-Dihydroxy vitamin D3 inhibits the Ras-MEK-ERK pathway and regulates proliferation and apoptosis of papillary thyroid carcinoma. Steroids 2020;159:108585. [PMID: 31982425 DOI: 10.1016/j.steroids.2020.108585] [Reference Citation Analysis]
46 shen J, Li C, Wen T, Yan L, Li B, Wang W, Yang J, Xu M, wen J. Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis. International Journal of Surgery 2017;44:33-42. [DOI: 10.1016/j.ijsu.2017.05.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
47 Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol 2017;66:537-44. [PMID: 27773614 DOI: 10.1016/j.jhep.2016.10.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
48 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
49 Zheng YF, Zhang XY, Bu YZ. LINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathway. J Cell Biochem 2019;120:4172-9. [PMID: 30548306 DOI: 10.1002/jcb.27704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
50 Sun Q, Zhang X, Tan Z, Gu H, Ding S, Ji Y. Bone marrow mesenchymal stem cells-secreted exosomal microRNA-205-5p exerts inhibitory effect on the progression of liver cancer through regulating CDKL3. Pathol Res Pract 2021;225:153549. [PMID: 34329837 DOI: 10.1016/j.prp.2021.153549] [Reference Citation Analysis]
51 Xie F, Sun L, Pang Y, Xu G, Jin B, Xu H, Lu X, Xu Y, Du S, Wang Y, Feng S, Sang X, Zhong S, Wang X, Sun W, Zhao H, Zhang H, Yang H, Huang P, Mao Y. Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine. Biomaterials 2021;265:120416. [PMID: 33007612 DOI: 10.1016/j.biomaterials.2020.120416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
52 Chang HJ, Zúñiga A, Conejero I, Voyvodic PL, Gracy J, Fajardo-Ruiz E, Cohen-Gonsaud M, Cambray G, Pageaux GP, Meszaros M, Meunier L, Bonnet J. Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples. Nat Commun 2021;12:5216. [PMID: 34471137 DOI: 10.1038/s41467-021-25538-y] [Reference Citation Analysis]
53 Zhu Z, Xiao T, Chang X, Hua Y, Gao J. Morusinol Exhibits Selective and Potent Antitumor Activity Against Human Liver Carcinoma by Inducing Autophagy, G2/M Cell Cycle Arrest, Inhibition of Cell Invasion and Migration, and Targeting of Ras/MEK/ERK Pathway. Med Sci Monit 2019;25:1864-70. [PMID: 30860205 DOI: 10.12659/MSM.912992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy. J Surg Res. 2017;209:102-111. [PMID: 28032546 DOI: 10.1016/j.jss.2016.10.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
55 Pascale RM, Feo F, Calvisi DF. An infernal cross-talk between oncogenic β-catenin and c-Met in hepatocellular carcinoma: Evidence from mouse modeling. Hepatology 2016;64:1421-3. [PMID: 27596836 DOI: 10.1002/hep.28790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 2016; 22(41): 9069-9095 [PMID: 27895396 DOI: 10.3748/wjg.v22.i41.9069] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 77] [Article Influence: 15.6] [Reference Citation Analysis]
57 Kröhler T, Kessler SM, Hosseini K, List M, Barghash A, Patial S, Laggai S, Gemperlein K, Haybaeck J, Müller R, Helms V, Schulz MH, Hoppstädter J, Blackshear PJ, Kiemer AK. The mRNA-binding Protein TTP/ZFP36 in Hepatocarcinogenesis and Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1754. [PMID: 31717307 DOI: 10.3390/cancers11111754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
58 McDevitt JL, Collard MD, Murphy RP, Sutphin PD, Yopp AC, Singal AG, Kalva SP. Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. Clin Imaging 2020;67:146-51. [PMID: 32659600 DOI: 10.1016/j.clinimag.2020.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
59 Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018;9:30869-82. [PMID: 30112114 DOI: 10.18632/oncotarget.25766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Wu C, Li P, Fan N, Han J, Zhang W, Zhang W, Tang B. A Dual-Targeting Functionalized Graphene Film for Rapid and Highly Sensitive Fluorescence Imaging Detection of Hepatocellular Carcinoma Circulating Tumor Cells. ACS Appl Mater Interfaces 2019;11:44999-5006. [DOI: 10.1021/acsami.9b18410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
61 Liu Y, Yan J, Wang F. Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients. Oncol Lett 2018;16:5733-8. [PMID: 30344728 DOI: 10.3892/ol.2018.9374] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Shiu JS, Hsieh MJ, Chiou HL, Wang HL, Yeh CB, Yang SF, Chou YE. Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics. Int J Med Sci 2018;15:1334-40. [PMID: 30275760 DOI: 10.7150/ijms.27059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
63 Liakopoulou E, Knuth A. Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality? Viszeralmedizin 2015;31:434-9. [PMID: 26889147 DOI: 10.1159/000442485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Dirchwolf M, Marciano S, Ruf AE, Singal AG, D'Ercole V, Coisson P, Zerega A, Orozco F, Palazzo A, Fassio E, Arufe D, Anders M, D'Amico C, Gaite L, Thompson M, Perez D, Haddad L, Demirdjian E, Zunino M, Gadano A, Murga MD, Bermudez C, Tomatis J, Grigera N, Antinucci F, Baravalle M, Gazari MMR, Ferreiro M, Barbero M, Curia A, Demonte M, Gualano G. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. Ann Hepatol 2021;25:100344. [PMID: 33819695 DOI: 10.1016/j.aohep.2021.100344] [Reference Citation Analysis]
65 Ni JY, Xu LF, Wang WD, Huang QS, Sun HL, Chen YT. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol 2017;143:199-207. [PMID: 27638772 DOI: 10.1007/s00432-016-2237-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Chen X, Calvisi DF. The dark side of the moon: AKT as a tumor suppressor in the liver?: Hepatology Elsewhere. Hepatology 2016;64:1358-61. [DOI: 10.1002/hep.28762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
67 Naeem S, Ali A, Qadri S, Khan Mashwani W, Tairan N, Shah H, Fayaz M, Jamal F, Chesneau C, Anam S. Machine-Learning Based Hybrid-Feature Analysis for Liver Cancer Classification Using Fused (MR and CT) Images. Applied Sciences 2020;10:3134. [DOI: 10.3390/app10093134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
68 Cui YQ, Liu YJ, Zhang F. The suppressive effects of Britannin (Bri) on human liver cancer through inducing apoptosis and autophagy via AMPK activation regulated by ROS. Biochem Biophys Res Commun 2018;497:916-23. [PMID: 29288670 DOI: 10.1016/j.bbrc.2017.12.144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
69 Wu X, Chen R, Zheng W, Hu H. Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer. Technol Cancer Res Treat 2018;17:1533033818759878. [PMID: 29739274 DOI: 10.1177/1533033818759878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
70 Qiu J, Peng B, Tang Y, Qian Y, Guo P, Li M, Luo J, Chen B, Tang H, Lu C, Cai M, Ke Z, He W, Zheng Y, Xie D, Li B, Yuan Y. CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. J Clin Oncol. 2017;35:734-742. [PMID: 28068175 DOI: 10.1200/jco.2016.68.2153] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 18.0] [Reference Citation Analysis]
71 Kim HY, Lee DH, Lee JH, Cho YY, Cho EJ, Yu SJ, Kim YJ, Yoon JH. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer 2018;18:307. [PMID: 29558905 DOI: 10.1186/s12885-018-4211-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
72 Fan A, Wei J, Yang M, Zhang Q, Zhang Y, Liu Q, Li N, Zhao D, Lu Y, Li J, Zhao J, Deng S, Zhang B, Zhu H, Chen X. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. European Journal of Pharmaceutical Sciences 2018;121:74-84. [DOI: 10.1016/j.ejps.2018.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
73 Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointest Endosc. 2018;88:230-239.e2. [PMID: 29317268 DOI: 10.1016/j.gie.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
74 Wang H, Ellipilli S, Lee WJ, Li X, Vieweger M, Ho YS, Guo P. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release 2021;330:173-84. [PMID: 33316298 DOI: 10.1016/j.jconrel.2020.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
75 Zhang E, Song B, Shi Y, Zhu H, Han X, Du H, Yang C, Cao Z. Fouling-resistant zwitterionic polymers for complete prevention of postoperative adhesion. Proc Natl Acad Sci U S A 2020;117:32046-55. [PMID: 33257542 DOI: 10.1073/pnas.2012491117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
76 Sun L, Wang Y, Cen J, Ma X, Cui L, Qiu Z, Zhang Z, Li H, Yang RZ, Wang C, Chen X, Wang L, Ye Y, Zhang H, Pan G, Kang JS, Ji Y, Zheng YW, Zheng S, Hui L. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 2019;21:1015-1026. [PMID: 31332348 DOI: 10.1038/s41556-019-0359-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
77 Luo D, Li H, Hu J, Zhang M, Zhang S, Wu L, Han B. Development and Validation of Nomograms Based on Gamma-Glutamyl Transpeptidase to Platelet Ratio for Hepatocellular Carcinoma Patients Reveal Novel Prognostic Value and the Ratio Is Negatively Correlated With P38MAPK Expression. Front Oncol 2020;10:548744. [PMID: 33344225 DOI: 10.3389/fonc.2020.548744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 222] [Article Influence: 72.7] [Reference Citation Analysis]
79 Hainaut P, Amadou A, Gormally E. Cancer prevention and control: hepatocellular carcinoma. Ecancermedicalscience 2019;13:949. [PMID: 31552122 DOI: 10.3332/ecancer.2019.949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
80 Huang C, Fang M, Feng H, Liu L, Li Y, Xu X, Wang H, Wang Y, Tong L, Zhou L, Gao C. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study. Int J Cancer 2021;149:717-27. [PMID: 33729545 DOI: 10.1002/ijc.33564] [Reference Citation Analysis]
81 van de Berg NJ, Meeuwsen FC, Doukas M, Kronreif G, Moelker A, van den Dobbelsteen JJ. Steerable needles for radio-frequency ablation in cirrhotic livers. Sci Rep 2021;11:309. [PMID: 33431965 DOI: 10.1038/s41598-020-77869-3] [Reference Citation Analysis]
82 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
83 Huang C, Xu X, Wang M, Xiao X, Cheng C, Ji J, Fang M, Gao C. Serum N-glycan fingerprint helps to discriminate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Electrophoresis 2021;42:1187-95. [PMID: 33570803 DOI: 10.1002/elps.202000392] [Reference Citation Analysis]
84 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
85 Moreno-Càceres J, Caballero-Díaz D, Nwosu ZC, Meyer C, López-Luque J, Malfettone A, Lastra R, Serrano T, Ramos E, Dooley S, Fabregat I. The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells. Cell Death Dis 2017;8:e3098. [PMID: 29022911 DOI: 10.1038/cddis.2017.469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
86 Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, Mallat A, Launoy G, Laurent A. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017;23:836-844. [PMID: 28295992 DOI: 10.1002/lt.24758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
87 Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66:412-423. [PMID: 27677712 DOI: 10.1016/j.jhep.2016.09.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
88 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
89 Moreno-Càceres J, Fabregat I. Apoptosis in liver carcinogenesis and chemotherapy. Hepat Oncol 2015;2:381-97. [PMID: 30191019 DOI: 10.2217/hep.15.27] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
90 Ahn HM, Ryu J, Song JM, Lee Y, Kim HJ, Ko D, Choi I, Kim SJ, Lee JW, Kim S. Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. Theranostics 2017;7:594-613. [PMID: 28255353 DOI: 10.7150/thno.15629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
91 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
92 Nie J, Gao Q, Fu J, He Y. Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review. Adv Healthcare Mater 2020;9:1901773. [DOI: 10.1002/adhm.201901773] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
93 Zhu Z, Xu L, Zhuang L, Ning Z, Zhang C, Yan X, Lin J, Shen Y, Wang P, Meng Z. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma. Onco Targets Ther. 2018;11:6731-6740. [PMID: 30349306 DOI: 10.2147/ott.s173275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
94 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
95 Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1). Med Sci Monit 2019;25:3212-20. [PMID: 31041919 DOI: 10.12659/MSM.913937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
96 Qu J, Lu W, Chen M, Gao W, Zhang C, Guo B, Yang J. Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer. Exp Ther Med 2020;20:18. [PMID: 32934683 DOI: 10.3892/etm.2020.9145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers (Basel). 2019;11. [PMID: 31100868 DOI: 10.3390/cancers11050681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
98 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
99 Wang X, Liao X, Yu T, Gong Y, Zhang L, Huang J, Yang C, Han C, Yu L, Zhu G, Qin W, Liu Z, Zhou X, Liu J, Han Q, Peng T. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol 2019;55:805-22. [PMID: 31485610 DOI: 10.3892/ijo.2019.4862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
100 Li W, Wang Y, Gao W, Zheng J. HCC with tumor thrombus entering the right atrium and inferior vena cava treated by percutaneous ablation. BMC Surg 2017;17:21. [PMID: 28245832 DOI: 10.1186/s12893-017-0217-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
101 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 156.2] [Reference Citation Analysis]
102 Sun HC, Xie L, Yang XR, Li W, Yu J, Zhu XD, Xia Y, Zhang T, Xu Y, Hu B, Du LP, Zeng LY, Ouyang J, Zhang W, Song TQ, Li Q, Shi YH, Zhou J, Qiu SJ, Liu Q, Li YX, Tang ZY, Shyr Y, Shen F, Fan J. Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. Chin Med J (Engl) 2017;130:2650-60. [PMID: 29133751 DOI: 10.4103/0366-6999.218019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
103 Zhao J, Li Q, Muktiali M, Ren B, Hu Y, Li D, Li Z, Li D, Xie Y, Tao M, Liang R. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. BMC Cancer 2020;20:812. [PMID: 32847533 DOI: 10.1186/s12885-020-07326-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 972] [Article Influence: 188.2] [Reference Citation Analysis]
105 He C, Zhang X, Li C, Peng W, Wen TF, Yan LN, Yang J, Lu W. Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. Oncotarget 2017;8:85599-611. [PMID: 29156744 DOI: 10.18632/oncotarget.20343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
106 Michael AE, Case JB, Massari F, Giuffrida MA, Mayhew PD, Carvajal JL, Regier PJ, Runge JJ, Singh A. Feasibility of laparoscopic liver lobectomy in dogs. Vet Surg 2021;50 Suppl 1:O89-98. [PMID: 33576085 DOI: 10.1111/vsu.13566] [Reference Citation Analysis]
107 Gorgen A, Goldaracena N, Zhang W, Sapisochin G. Intrahepatic cholangiocarcinoma, are we making progress? Hepatobiliary Surg Nutr 2018;7:127-9. [PMID: 29744342 DOI: 10.21037/hbsn.2017.12.14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 He K, Liu S, Xia Y, Xu J, Liu F, Xiao J, Li Y, Ding Q, Lu L, Xiang G, Zhan M. CXCL12 and IL7R as Novel Therapeutic Targets for Liver Hepatocellular Carcinoma Are Correlated With Somatic Mutations and the Tumor Immunological Microenvironment. Front Oncol 2020;10:574853. [PMID: 33344233 DOI: 10.3389/fonc.2020.574853] [Reference Citation Analysis]
109 Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV. A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol. 2016;89:263-272. [PMID: 26668215 DOI: 10.1124/mol.115.101360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
110 Li IH, Shih JH, Tsai CS, Chien WC, Kao HH, Pan KT, Cheng YD, Kao LT. Inverse Association of Fibrates and Liver Cancer: A Population-Based Case-Control Study in Taiwan. J Clin Pharmacol 2019;59:1170-6. [PMID: 30964561 DOI: 10.1002/jcph.1419] [Reference Citation Analysis]
111 Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol 2020;30:5663-73. [PMID: 32424595 DOI: 10.1007/s00330-020-06931-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
112 Liu G, Liu G, Cui X, Xu Y. Transcriptomic Data Analyses Reveal a Reprogramed Lipid Metabolism in HCV-Derived Hepatocellular Cancer. Front Cell Dev Biol 2020;8:581863. [PMID: 33195224 DOI: 10.3389/fcell.2020.581863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Shen J, Wen T, Chen W, Lu C, Yan L, Yang J. Model predicting the microvascular invasion and satellite lesions of hepatocellular carcinoma after hepatectomy. ANZ J Surg 2018;88:E761-6. [PMID: 29687553 DOI: 10.1111/ans.14473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
114 Wu C, Qi X, Qiu Z, Deng G, Zhong L. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC. Aging (Albany NY) 2021;13:22148-63. [PMID: 34491228 DOI: 10.18632/aging.203494] [Reference Citation Analysis]
115 Cristaudi A, Barizzi J, Rosso R, Varini M, Alerci M, Rubbia Brandt L, Majno P, Balzarotti Canger RC. Medullary-like hepatocellular carcinoma. J Surg Case Rep 2018;2018:rjy010. [PMID: 29435219 DOI: 10.1093/jscr/rjy010] [Reference Citation Analysis]
116 Wang S, Zhang S, He Y, Huang X, Hui Y, Tang Y. HOXA11‐AS regulates JAK‐STAT pathway by miR‐15a‐3p/STAT3 axis to promote the growth and metastasis in liver cancer. J Cell Biochem 2019;120:15941-51. [DOI: 10.1002/jcb.28871] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
117 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 19.5] [Reference Citation Analysis]
118 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
119 Schellhaas B, Strobel D, Stumpf M, Ganslmayer M, Pfeifer L, Goertz RS, Neurath MF, Zopf S. Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts. European Journal of Gastroenterology & Hepatology 2018;30:1422-7. [DOI: 10.1097/meg.0000000000001221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Hu CL, Zhang YJ, Zhang XF, Fei X, Zhang H, Li CG, Sun B. 3D Culture of Circulating Tumor Cells for Evaluating Early Recurrence and Metastasis in Patients with Hepatocellular Carcinoma. Onco Targets Ther 2021;14:2673-88. [PMID: 33888992 DOI: 10.2147/OTT.S298427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Piñero F, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Coronel M, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Rubinstein F, Silva M; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018;30:376-83. [PMID: 29509603 DOI: 10.1097/MEG.0000000000001049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
122 Okubo S, Ohta T, Shoyama Y, Uto T. Arctigenin suppresses cell proliferation via autophagy inhibition in hepatocellular carcinoma cells. J Nat Med 2020;74:525-32. [PMID: 32207025 DOI: 10.1007/s11418-020-01396-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
123 Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol 2021;361:104295. [PMID: 33508529 DOI: 10.1016/j.cellimm.2021.104295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 van Dijk F, Olinga P, Poelstra K, Beljaars L. Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma. Front Med (Lausanne). 2015;2:72. [PMID: 26501061 DOI: 10.3389/fmed.2015.00072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
125 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
126 Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2448-2452 [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
127 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
128 Liu G, Liu R, Shan Y, Sun C. Marine bacterial exopolysaccharide EPS11 inhibits migration and invasion of liver cancer cells by directly targeting collagen I. J Biol Chem 2021;297:101133. [PMID: 34461092 DOI: 10.1016/j.jbc.2021.101133] [Reference Citation Analysis]
129 Wang X, Xu N, Li Q, Chen S, Cheng H, Yang M, Jiang T, Chu J, Ma X, Yin D. Lactonic sophorolipid-induced apoptosis in human HepG2 cells through the Caspase-3 pathway. Appl Microbiol Biotechnol 2021;105:2033-42. [PMID: 33582833 DOI: 10.1007/s00253-020-11045-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Liu X, Sun Y, Xu S, Gao X, Kong F, Xu K, Tang B. Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma. Theranostics 2019;9:5828-38. [PMID: 31534522 DOI: 10.7150/thno.34837] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
131 Shen J, Wen J, Li C, Wen T, Yan L, Li B, Yang J, Lu C. The prognostic value of microvascular invasion in early-intermediate stage hepatocelluar carcinoma: a propensity score matching analysis. BMC Cancer 2018;18:278. [PMID: 29530006 DOI: 10.1186/s12885-018-4196-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
132 Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. J Clin Med 2019;8:E903. [PMID: 31238554 DOI: 10.3390/jcm8060903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
133 Naseer M, Hadi S, Syed A, Safdari A, Tahan V. Exosomes: A new frontier under the spotlight for diagnosis and treatment of gastrointestinal diseases. World J Meta-Anal 2021; 9(1): 12-28 [DOI: 10.13105/wjma.v9.i1.12] [Reference Citation Analysis]
134 Ding L, Wei F, Wang N, Sun Y, Wang Q, Fan X, Qi L, Wang S. Tertiary sulphonamide derivatives as dual acting small molecules that inhibit LSD1 and suppress tubulin polymerisation against liver cancer. J Enzyme Inhib Med Chem 2021;36:1563-72. [PMID: 34281464 DOI: 10.1080/14756366.2021.1917564] [Reference Citation Analysis]
135 Yi Y, Yu MC, Fu PY, Liu G, Zhou PY, Guan RY, Zhou C, Sun BY, Qiu SJ. MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β-catenin and predicts poor prognosis. Liver Int 2021;41:1409-20. [PMID: 33506565 DOI: 10.1111/liv.14803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Grąt M, Wronka KM, Stypułkowski J, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Grąt K, Patkowski W, Krawczyk M. The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol 2017;24:526-34. [PMID: 27531306 DOI: 10.1245/s10434-016-5500-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
137 He C, Peng W, Li C, Wen TF. Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e8540. [PMID: 29137062 DOI: 10.1097/MD.0000000000008540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
138 Yan J, Cao J, Chen Z. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes. BMC Cancer 2021;21:175. [PMID: 33602168 DOI: 10.1186/s12885-021-07886-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Li K, Su Z, Xu E, Huang Q, Zeng Q, Zheng R. Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients. BMC Cancer 2017;17:61. [PMID: 28103837 DOI: 10.1186/s12885-017-3061-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]